Pipeline
Forest small banner

Glycostem’s pipeline has the potential to redefine standards of care across various type of cancer where there is an urgent medical need.

Therapy
Product
Indication
Cell
Development
Pre-clinical
Phase I
Phase II
Phase III
Partner

oNKord®

Inaleucel
AML
NK Cell
Phase II

medac (EU)

inno.N (Japan and Korea)

oNKord®
Inaleucel
AML
NK Cell
II
2025

medac (EU)

inno.N (Japan and Korea)

Inaleucel
MM
NK Cell
Phase I

medac (EU)

inno.N (Japan and Korea)

oNKord®
Inaleucel
MM
NK Cell
I
2025

medac (EU)

inno.N (Japan and Korea)

Inaleucel
Melanoma
NK Cell
Development

Glycostem

oNKord®
Inaleucel
Melanoma
NK Cell
DEV
TBA

Glycostem

Inaleucel
N/D
Combination Therapy
Development

Glycostem

oNKord®
Inaleucel
N/D
Combination Therapy
DEV
TBA

Glycostem

viveNK™

GTA103
Glioblastoma
CAR-NK
Development

inno.N (Japan and Korea)

viveNK™
GTA103
Glioblastoma
CAR-NK
DEV
TBA

inno.N (Japan and Korea)

GTA103
N/A
CAR-NK
Development

Glycostem

viveNK™
GTA103
N/A
CAR-NK
DEV
TBA

Glycostem

GTA201
N/D
TCR-NK
Development

Glycostem

viveNK™
GTA201
N/D
TCR-NK
DEV
TBA

Glycostem

Therapy
Phase
Partner

oNKord®

Inaleucel
AML
NK Cell
Phase II

medac (EU)

inno.N (Japan and Korea)

oNKord®
Inaleucel
AML
NK Cell
II
2025

medac (EU)

inno.N (Japan and Korea)

Inaleucel
MM
NK Cell
Phase I

medac (EU)

inno.N (Japan and Korea)

oNKord®
Inaleucel
MM
NK Cell
I
2025

medac (EU)

inno.N (Japan and Korea)

Inaleucel
Melanoma
NK Cell
Development

Glycostem

oNKord®
Inaleucel
Melanoma
NK Cell
DEV
TBA

Glycostem

Inaleucel
N/D
Combination Therapy
Development

Glycostem

oNKord®
Inaleucel
N/D
Combination Therapy
DEV
TBA

Glycostem

viveNK™

GTA103
Glioblastoma
CAR-NK
Development

inno.N (Japan and Korea)

viveNK™
GTA103
Glioblastoma
CAR-NK
DEV
TBA

inno.N (Japan and Korea)

GTA103
N/A
CAR-NK
Development

Glycostem

viveNK™
GTA103
N/A
CAR-NK
DEV
TBA

Glycostem

GTA201
N/D
TCR-NK
Development

Glycostem

viveNK™
GTA201
N/D
TCR-NK
DEV
TBA

Glycostem